دورية أكاديمية
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges:A Post-Hoc Analysis of Data from ETHOS
| العنوان: | Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges:A Post-Hoc Analysis of Data from ETHOS |
|---|---|
| المؤلفون: | Bafadhel, Mona, Rabe, Klaus F., Martinez, Fernando J., Singh, Dave, Darken, Patrick, Jenkins, Martin, Aurivillius, Magnus, Patel, Mehul, Dorinsky, Paul |
| المصدر: | Bafadhel , M , Rabe , K F , Martinez , F J , Singh , D , Darken , P , Jenkins , M , Aurivillius , M , Patel , M & Dorinsky , P 2022 , ' Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges : A Post-Hoc Analysis of Data from ETHOS ' , International journal of chronic obstructive pulmonary disease , vol. 17 , pp. 3061-3073 . https://doi.org/10.2147/COPD.S374670Test |
| سنة النشر: | 2022 |
| المجموعة: | King's College, London: Research Portal |
| مصطلحات موضوعية: | eosinophils, inhaled corticosteroids, triple therapy |
| الوصف: | Purpose: Blood eosinophil (EOS) count can guide treatment decisions for chronic obstructive pulmonary disease (COPD). In the 52-week ETHOS study (NCT02465567), budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) triple therapy at two inhaled corticosteroid doses reduced moderate/severe exacerbation rates and improved lung function, symptoms, and disease-related quality of life (QoL) versus dual therapy with glycopyrronium/formoterol fumarate dihydrate (GFF) or budesonide/formoterol fumarate dihydrate (BFF) in patients with moderate-to-very severe COPD. This subgroup analysis evaluated treatment benefits in ETHOS by baseline EOS count. Methods: Patients (40-80 years) with a COPD history were randomly assigned 1:1:1:1 to receive BGF 320/14.4/10 µg, BGF 160/14.4/10 µg, GFF 14.4/10 µg, or BFF 320/10 µg via a metered-dose inhaler. This post-hoc analysis assessed endpoints by baseline EOS count using Global Initiative for Obstructive Lung Disease thresholds (<100, ≥100, ≥100-<300, ≥300 cells/mm3), and investigated continuous relationships between treatment effects and EOS count on exacerbations, symptoms, disease-related QoL, lung function, and safety. Results: In the modified intention-to-treat population (n=8509), 82.6% had EOS counts ≥100 cells/mm3. BGF 320 reduced moderate/severe exacerbation rates versus GFF in the ≥100, ≥100-<300, and ≥300 subgroups; treatment differences increased with EOS count. BGF 320 improved rescue medication use and lung-function outcomes across all subgroups, and St George's Respiratory Questionnaire total score, Transition Dyspnea Index focal score, and Exacerbations of Chronic Pulmonary Disease Tool total score in all except the <100 subgroup versus GFF. Benefits of BGF 320 versus BFF were generally consistent across subgroups. Safety data were comparable across subgroups. Conclusion: Benefits of BGF versus GFF were observed across EOS counts, particularly at ≥100 cells/mm³; versus BFF, benefits were largely independent of EOS. These findings confirm that benefits ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| DOI: | 10.2147/COPD.S374670 |
| الإتاحة: | https://doi.org/10.2147/COPD.S374670Test https://kclpure.kcl.ac.uk/portal/en/publications/9de07b9a-cf95-46c5-8572-cd5d3841c6c6Test https://kclpure.kcl.ac.uk/ws/files/195927352/Benefits_of_Budesonide_BAFADHEL_Published6December2022_GOLD_VoR_CC_BY_NC_.pdfTest http://www.scopus.com/inward/record.url?scp=85143994804&partnerID=8YFLogxKTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.96B307ED |
| قاعدة البيانات: | BASE |
| DOI: | 10.2147/COPD.S374670 |
|---|